September 15, 2026
On September 14, Curaleaf asked the Alberta Securities Commission for an expedited hearing and an order stopping Aurora Cannabis from selling more shares into the market while Curaleaf's takeover offer is open. By Curaleaf's count, Aurora has issued about 2.81 million shares at an average of US$3.04 since June, diluting holders by roughly 4.9 percent and adding more than US$11 million to the cost of the bid.
"Every Share Aurora sells below the Offer price raises the same question," Boris Jordan, Curaleaf's chairman and CEO, said in the filing announcement. "If management believes US$4.00 undervalues the company and the company has ample cash, why continue diluting its shareholders?"
The Curaleaf Aurora takeover is the first hostile bid in the sector since 2019, and it has moved from a valuation argument to a procedural one in under a month.
Curaleaf announced its intention on August 11 and commenced the offer on August 18: 0.3463 Curaleaf shares plus US$0.75 in cash for each Aurora share, about US$4.00 at announcement and a 45 percent premium to Aurora's unaffected price. The offer runs until December 1 unless extended.
Aurora's board took two weeks and unanimously recommended rejection on September 2. Its directors' circular makes seven arguments, and three carry the weight:
Aurora also argues the bid was never properly commenced: the December 1 expiry falls short of Canada's 105-day minimum deposit period, and a required French-language notice was not published in Quebec. Those are the kinds of objections that end up in front of a securities commission, which is where the fight now is.
The strategic case has nothing to do with U.S. dispensaries. On its August 5 earnings call, Curaleaf disclosed that only about 20 percent of its international supply comes from its own facilities, with a target of 50 to 75 percent within six to twelve months. It owns one small site in Portugal with no EU-GMP certification.
Aurora is the opposite. It runs four EU-GMP facilities totaling about 353,400 square feet, supplies 72 percent of its own international demand, and grew European revenue from C$41.0 million in fiscal 2024 to C$131.8 million in fiscal 2026. A U.S. operator cannot export cannabis grown under a state license. Buying Aurora is the shortest path to Germany, Australia, and Poland with product it controls.
Aurora is not sitting still. On August 19, the day after the bid launched, it bought two U.K. pharma businesses for £2.1 million. On September 8, it hired Faris El Refaie, a 25-year biopharma executive, as executive vice president of global commercial, effective September 28. Both moves make the company look more like a pharmaceutical supplier and less like a target, and both cost money that Curaleaf says came from selling shares below its offer price.
Three things decide this before December 1.
The Alberta Securities Commission rules on whether an at-the-market program is a legitimate financing or a defensive tactic. Aurora says the proceeds are for "strategic, accretive" purposes. Curaleaf says the program has diluted holders 10.8 percent since February.
Aurora shareholders decide whether 0.3463 Curaleaf shares are worth more than an Aurora share. Aurora's stock trades about C$11.8 million a day against Curaleaf's C$8.8 million, and Aurora notes that holders in 29 U.S. states would receive forced-sale proceeds rather than Curaleaf stock. A shareholder who likes the Curaleaf story can already buy it without a tender.
A third party may show up. Aurora has said it is exploring alternatives, and a debt-free company with C$149 million in cash and four GMP plants is a cleaner asset than most in this industry.
Curaleaf is one of the largest U.S. operators, and through December 1 its chairman's attention and a meaningful amount of its stock are pointed at a Canadian company. The dispensary owners competing with its stores are not. The cash component of the bid is about US$0.75 a share; the rest is Curaleaf equity, which is why the fight is about dilution rather than financing. A company issuing stock for an acquisition while carrying US$1 billion in debt is unlikely to be loosening store-level budgets this quarter.
The reverse read is Aurora's playbook. Its defense is built on owning production and reducing dependence on outside suppliers, which is the same argument U.S. operators made for vertical integration and are now walking back state by state. Which side is right about supply chains matters more to a vendor than who ends up owning whom.
What is Curaleaf offering for Aurora? 0.3463 Curaleaf shares plus US$0.75 cash per Aurora share, about US$4.00 at announcement, open until December 1, 2026.
Why did Aurora reject the bid? Its board said the price undervalues the company, the exchange ratio gives Aurora holders 7.7 percent of the equity but 3.2 percent of the votes, and the deal shifts Curaleaf's debt onto a debt-free shareholder base.
What did Curaleaf ask the Alberta Securities Commission for? An order halting Aurora's at-the-market share sales while the offer is open, on the grounds that the sales dilute holders and raise the cost of the bid.
Is the deal likely to close? It has no board support, a disputed commencement, a regulator involved, and a target actively spending to make itself harder to buy. That is a long list for eleven weeks.
One of the largest U.S. operators is spending its fall on a Canadian fight. Its competitors are not. See verified, owner-level dispensary contacts across six states, refreshed weekly. Free preview at holdenleads.com.
Holden Leads
Holden Leads tracks every licensed dispensary across California, Michigan, Illinois, Massachusetts, New York, Colorado, Oregon, Washington, Nevada, and Maine — cross-referenced weekly against official state regulatory databases and enriched with phone numbers, emails, websites, and social profiles. Stop manually hunting for contact info. Get the full list today.